BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report for the period January – December 2020

Thu, Feb 04, 2021 08:00 CET

New data provides further support for BAN2401 (lecanemab)Key events during the fourth quarter 2020 · BioArctic’s drug candidate BAN2401 was assigned an international nonproprietary name (INN): lecanemab. · Further data for drug candidate lecanemab (BAN2401) from the Phase 2b open-label extension study were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Impact of COVID-19 on the company has been limited · The spread and negative effects of the coronavirus during the year had a serious impact on society, the economy and the lives of private

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report for the period January – December 2020

Subscribe

Media

Share

About Us

Interim Report for the period January – December 2020

Subscribe

Media